Axi-cel in CNS Lymphoma

Inclusion Criteria: * Patients with relapsed/refractory active primary or secondary CNS lymphoma, histologically proven aggressive B cell lymphoma, including DLBCL, HGBL, PMBL, or tFL, and defined by the following categories: * Primary CNS lymphoma, relapsed or refractory following at least one line of CNS-directed therapy. There is no restriction on the number of recurrences. * Secondary CNS lymphoma, relapsed or refractory following at least one line of CNS-directed therapy for prophylaxis or treatment of CNS lymphoma. * Radiographically event CNS disease by MRI of the brain (ie enhancing lesion on gadolinium enhanced MRI) * For patients with secondary CNSL with concurrent systemic lymphoma, the concurrent systemic lymphoma must be either DLBCL, PMBL, high grade B cell lymphoma, or transformed lymphoma and must have relapsed following at least 1 prior lines of therapy (which must have included an anti-CD20 monoclonal antibody (unless the tumor is CD20 negative) and an anthracycline * At least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed since any prior systemic cancer therapy at the time the subject provides consent * Age 18 years or older at the time of informed consent * ECOG performance status of 0 or 1 * Adequate bone marrow, renal, hepatic, pulmonary and cardiac function defined as: * Absolute neutrophil count (ANC) ≥1000/μL * Platelet count ≥ 75,000/μL * Absolute lymphocyte count ≥ 100/μL * Creatinine clearance (as estimated by C…